Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study

Anoja W Gunaratne, Harrison Hamblin, Annabel Clancy, Aleja Jane Marie C Magat, Marie Vic M Dawson, Jeffrey Tu, Thomas J Borody, Anoja W Gunaratne, Harrison Hamblin, Annabel Clancy, Aleja Jane Marie C Magat, Marie Vic M Dawson, Jeffrey Tu, Thomas J Borody

Abstract

Background: Vonoprazan fumarate is a novel potassium-competitive acid blocker more effective in suppressing acid production than proton pump inhibitors (PPIs) and when combined with antibiotics has been used to eradicate Helicobacter pylori (H. pylori) infection. However, it has not yet been examined in an Australian setting. This study aimed to report on the efficacy and safety of vonoprazan-containing antibiotic combination therapies in the eradication of H. pylori.

Methods: A single-center, exploratory, clinical review of patients 18 years or over, positive for H. pylori on Urea Breath Test (UBT), and/or histopathology who underwent a 10-day treatment of combination antibiotics plus vonoprazan between January 2017 and September 2019 was conducted. Eleven different combinations of antibiotics that included 2-5 different antibiotics predominantly amoxicillin, rifabutin, levofloxacin, furazolidone, nitazoxanide, and tetracycline were included. The eradication success was based on negative UBT results and/or histopathology results after the treatment. Descriptive statistics were summarized.

Results: One hundred and fifty-three patients (Female n = 74, 48%) with a positive for H. pylori were treated with vonoprazan-containing antibiotic combination therapy during the study period. Of the 153 patients, 48 (31%) had previously failed a PPI-based H. pylori treatment. Follow-up was available for 66/153 (43%) patients. In those who completed follow-up, overall eradication was achieved in 97% (64/66) of patients. In the subgroup of patients treated for the first time, eradication was achieved in 100% (44/44). In those who had failed prior, non-vonoprazan-containing treatment, eradication was achieved in 91% (20/22) of patients.

Conclusions: Vonoprazan-containing antibiotic therapy is an effective H. pylori eradication treatment. It is capable of achieving 100% efficacy in patients treated for the first time and even 91% efficacy in patients with previous eradication failure. Subsequent studies utilizing a factorial design will be needed to optimize each regimen as most regimens contained more than two antibiotics.

Keywords: Helicobacter pylori; antibiotics; potassium-competitive acid blockers; proton pump inhibitors; urea breath test.

Conflict of interest statement

TJB has a pecuniary interest in the Centre for Digestive Diseases in Australia and reports research grant funds from Finch Therapeutics, USA. TJB’s patents for H. pylori treatment combinations: filed: WO2019071290, AU2018348777, CA3049033, CN201880014978.X, EP18865750.6, NZ754962, US16/451781, ZA201904387, and AU2020050384; pending: US20190314355, CN110366415, and EP3551186; granted; US6489317‐B1, US9050263‐B2, AU762890‐B2, CA2330424‐C, and WO0203065‐A1. AWG, AC, AJM, MVD, JT, and HH have no disclosures.

© 2021 The Authors. Helicobacter published by John Wiley & Sons Ltd.

References

    1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1(8336):1273‐1275.
    1. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19(3):449‐490.
    1. Zamani M, Ebrahimtabar F, Zamani V, et al. Systematic review with meta‐analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2018;47(7):868‐876.
    1. Windsor HM, Abioye‐Kuteyi EA, Leber JM, et al. Prevalence of Helicobacter pylori in indigenous Western Australians: comparison between urban and remote rural populations. Med J Aust. 2005;182:210‐213.
    1. Schöttker B, Adamu MA, Weck MN, et al. Helicobacter pylori infection is strongly associated with gastric and duodenal ulcers in a large prospective study. Clin Gastroenterol Hepatol. 2012;10(5):487‐493.
    1. Dunne C, Dolan B, Clyne M. Factors that mediate colonization of the human stomach by Helicobacter pylori . World J Gastroenterol. 2014;20(19):5610‐5624.
    1. Lee SW, Chang CS, Lee TY, et al. Risk factors and therapeutic response in Chinese patients with peptic ulcer disease. World J Gastroenterol. 2010;16(16):2017‐2022.
    1. Gao L, Weck MN, Stegmaier C, et al. Alcohol consumption, serum gamma‐glutamyl transferase, and Helicobacter Pylori infection in a population‐based study among 9733 older adults. Ann Epidemiol. 2010;20(2):122‐128.
    1. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID‐related ulcer complications. Practice parameters committee of the American College of gastroenterology. Am J Gastroenterol. 2009;104(3):728‐738.
    1. Kuipers EJ, Uyterlinde AM, Peña AS, et al. Long‐term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345(8964):1525‐1528.
    1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans . Schistosomes, liver flukes and Helicobacter pylori . IARC Monogr Eval Carcinog Risks Hum. 1994;61:1‐241.
    1. Lipof T, Shapiro D, Kozol RA. Surgical perspectives in peptic ulcer disease and gastritis. World J Gastroenterol. 2006;12(20):3248‐3252.
    1. Eslick GD, Tilden D, Arora N, et al. Clinical and economic impact of “triple therapy” for Helicobacter pylori eradication on peptic ulcer disease in Australia. Helicobacter. 2020;25:e12751.
    1. Malfertheiner P, Schulz C. Peptic ulcer: chapter closed? Dig Dis. 2020;38(Suppl 2):112‐116.
    1. Brimblecombe RW, Duncan WAM, Durant GJ, et al. Cimetidine‐a non‐thiourea H2‐receptor antagonist. J Int Med Res. 1975;3:86‐92.
    1. Brimblecombe RW, Duncan WA, Durant GJ, et al. Characterization and development of cimetidine as a histamine H2‐receptor antagonist. Gastroenterology. 1978;74(2):339‐347.
    1. Borody TJ, Cole P, Noonan S, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust. 1989;151(8):431‐435.
    1. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10(6):528‐534.
    1. Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157(1):44‐53.
    1. Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212‐239.
    1. Alarcón T, Domingo D, López‐Brea M. Antibiotic resistance problems with Helicobacter pylori . Int J Antimicrob Agents. 1999;12(1):19‐26.
    1. Schubert JP, Gehlert J, Rayner CK, et al. Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: a systematic review and meta‐analysis. J Gastroenterol Hepatol. 2021;36(6):1450‐1456. 10.1111/jgh.15352.
    1. Sugimoto M, Yamaoka Y. Role of vonoprazan in Helicobacter pylori eradication therapy in Japan. Font. Pharmacol. 2019;9:1560. 10.3389/fphar.2018.01560.
    1. Yang X, Li Y, Sun Y, et al. Vonoprazan: a novel and potent alternative in the treatment of acid‐related diseases. Dig Dis Sci. 2018;63(2):302‐311.
    1. Hori Y, Imanishi A, Matsukawa J, et al. 1‐[5‐(2‐Fluorophenyl)‐1‐(pyridin‐3‐ylsulfonyl)‐1H‐pyrrol‐3‐yl] ‐N‐methylmethanamine monofumarate (TAK‐438), a novel and potent potassium‐competitive acid blocker for the treatment of acid‐related diseases. J Pharmacol Exp Ther. 2010;335(1):231‐238.
    1. Sugano K. Vonoprazan fumarate, a novel potassium‐competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018;11:1756283X17745776.
    1. Lyu QJ, Pu QH, Zhong XF, et al. Efficacy and safety of vonoprazan‐based versus proton pump inhibitor‐based triple therapy for Helicobacter pylori eradication: a meta‐analysis of randomized clinical trials. Biomed Res Int. 2019;2019:9781212.
    1. Oshima T, Miwa H. Potent potassium‐competitive acid blockers: a new era for the treatment of acid‐related diseases. J Neurogastroenterol Motil. 2018;24(3):334‐344.
    1. Shinozaki S, Kobayashi Y, Osawa H, et al. Effectiveness and safety of vonoprazan versus proton pump inhibitors for second‐line Helicobacter pylori eradication therapy: systematic review and meta‐analysis. Digestion. 2021;102(3):319‐325.
    1. Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium‐competitive acid blocker, as a component of first‐line and second‐line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double‐blind study. Gut. 2016;65(9):1439‐1446.
    1. Li M, Oshima T, Horikawa T, et al. Systematic review with meta‐analysis: vonoprazan, a potent acid blocker, is superior to proton‐pump inhibitors for eradication of clarithromycin‐resistant strains of Helicobacter pylori . Helicobacter. 2018;23(4):e12495.
    1. Kiyotoki S, Nishikawa J, Sakaida I. Efficacy of vonoprazan for Helicobacter pylori eradication. Intern Med. 2020;59(2):153‐161.
    1. Graham DY, Canaan Y, Maher J, et al. Rifabutin‐based triple therapy (RHB‐105) for Helicobacter pylori eradication: a double‐blind, randomized, controlled trial. Ann Intern Med. 2020;172(12):795‐802.
    1. Stenstroem B, Mendis A, Marshall B. Helicobacter pylori: the latest in diagnosis and treatment. Aust Fam Physician. 2008;37:608‐612.
    1. Moujaber T, MacIntyre CR, Backhouse J, et al. The sero‐epidemiology of Helicobacter pylori infection in Australia. Int J Infect Dis. 2008;12:500‐504.
    1. Miftahussurur M, Pratama Putra B, Yamaoka Y. The potential benefits of vonoprazan as Helicobacter pylori infection therapy. Pharmaceuticals (Basel). 2020;13(10):276.
    1. Jung YS, Kim EH, Park CH. Systematic review with meta‐analysis: the efficacy of vonoprazan‐based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther. 2017;46(2):106‐114.
    1. Miehlke S, Kirsch C, Schneider‐Brachert W, et al. A prospective, randomized study of quadruple therapy and high‐dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter. 2003;8(4):310‐319.
    1. Hirata Y, Yamada A, Niikura R, et al. Efficacy and safety of a new rifabutin‐based triple therapy with vonoprazan for refractory Helicobacter pylori infection: a prospective single‐arm study. Helicobacter. 2020;25:e12719.
    1. Suzuki S, Gotoda T, Kusano C, et al. Seven‐day vonoprazan and low‐dose amoxicillin dual therapy as first‐line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut. 2020;69:1019‐1026.
    1. Megraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004;53(9):1374‐1384.
    1. Ashida K, Sakurai Y, Hori T, et al. Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther. 2016;43:240‐251.
    1. Maruyama M, Tanaka N, Kubota D, et al. Vonoprazan‐based regimen is more useful than PPI‐based one as a first‐line Helicobacter pylori eradication: a randomized controlled trial. Can. J Gastroenterol Hepatol. 2017;2017:4385161.
    1. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis. 2010;19:409‐414.
    1. Yaxley J, Chakravarty B. Helicobacter pylori eradication – an update on the latest therapies. Aust Fam Physician. 2014;43(5):301‐305.
    1. Borody TJ, Pang G, Wettstein AR, et al. Efficacy and safety of rifabutin‐containing ‘rescue therapy’ for resistant Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;23(4):481‐488.
    1. Furuta T, Yamade M, Kagami T, et al. Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori . Digestion. 2020;101(6):743‐751. 10.1159/000502287.
    1. Graham DY. Transitioning of Helicobacter pylori therapy from trial and error to antimicrobial stewardship. Antibiotics (Basel). 2020;9(10):671.
    1. Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol. 2017;14:383‐384.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe